Table 2.
The incidence rate and hazard ratio (HR) of 5 major events in EV cohort and control group.
| Outcomes | With EV | Without EV | Crude HR | Adjusted HR* | ||||
|---|---|---|---|---|---|---|---|---|
| (95% CI) | (95% CI) | |||||||
| Event | PYs | Rate | Event | PYs | Rate | |||
| ADHD | 497 | 177,328 | 28.0 | 658 | 308,504 | 21.3 | 1.30 (1.16–1.46) | 1.25 (1.11–1.41) |
| Epilepsy | 245 | 178,880 | 13.7 | 331 | 310,557 | 10.7 | 1.27 (1.08–1.50) | 1.25 (1.06–1.47) |
| Asthma | 2,343 | 156,650 | 150 | 2,663 | 286,305 | 93.0 | 1.56 (1.48–1.65) | 1.49 (1.41–1.58) |
| Allergic rhinitis | 5,812 | 125,691 | 462 | 7,677 | 243,124 | 316 | 1.42 (1.37–1.47) | 1.37 (1.33–1.42) |
| Atopic dermatitis | 791 | 173,414 | 45.6 | 1,188 | 302,104 | 39.3 | 1.14 (1.05–1.25) | 1.09 (0.99–1.19) |
Model adjusted for age, sex, parental occupation, and urbanization of residence.
ADHD, Attention Deficit/Hyperactivity Disorder; EV, enterovirus; HR, hazard ratio; PYs, person-years; Rate, incidence rate, per 10,000 person-years.